OncoKB New Data Release - January 30, 2025
Contact OncoKB
Data Release v4.25
January 30, 2025
What's New
Happy New Year! As of January 30, 2025, fifteen Level 1, twelve Level 2, eighteen Level 3 and eleven Level 4 treatments for unique biomarker-selected indications were added to OncoKB. A table summarizing these changes can be found here. The Precision Oncology: 2024 in review article can be found here.
Updated Therapeutic Implications:
New alteration(s) with a tumor type-specific level of evidence
Promotion of tumor type-specific level of evidence for an alteration
Addition of drug(s) associated with a tumor type-specific leveled alteration(s) currently in OncoKB™ (without changing the alteration's highest level of evidence)
Level 1: Addition of Ensartinib to ALK Fusions in non-small cell lung cancer based on FDA approval of Ensartinib in ALK-positive non-small cell lung cancer (PMID: 34473194)
Level 1 sensitivity-associated evidence currently in OncoKB™ for ALK Fusions in non-small cell lung cancer: Alectinib, Brigatinib, Certinib, Crizotinib, Lorlatinib)
Level 1: Addition of Sotorasib + Panitumumab to KRAS G12C in colorectal cancer based on FDA approval of Sotorasib with Panitumumab for KRAS G12C-mutated colorectal cancer (PMID: 37870968)
Level 1 sensitivity-associated evidence currently in OncoKB™ for KRAS G12C in colorectal cancer: Adagrasib + Cetuximab
Level R1 resistance-associated evidence currently in OncoKB™ for KRAS G12C in colorectal cancer: Cetuximab, Panitumumab, Tucatinib + Trastuzumab
Gene Curation:
Addition of 2 new genes:
We're Here to Help
As always, don’t hesitate to reach out if you have comments, questions or suggestions. We love to hear from you. You can reach us at con...@oncokb.org
